Shares of Lilly and Novo Nordisk are trading lower on reports suggesting the EMA this will meet to discuss the possible link between GLP-1 drugs and suicidal thoughts. Stocks across sectors are also lower ahead of Wednesday inflation data.
Portfolio Pulse from Benzinga Newsdesk
Shares of Lilly (LLY) and Novo Nordisk (NVO) are trading lower due to reports that the EMA will discuss a potential link between GLP-1 drugs and suicidal thoughts. The broader market is also down in anticipation of upcoming inflation data.
April 09, 2024 | 5:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lilly's stock is trading lower amid concerns over a potential link between its GLP-1 drugs and suicidal thoughts, as the EMA plans a review.
The news of the EMA's meeting to discuss GLP-1 drugs potentially linked to suicidal thoughts directly impacts Lilly's stock due to the company's involvement in the production of these drugs. The negative sentiment surrounding this news is likely to cause short-term bearish pressure on LLY shares.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Novo Nordisk's shares are down following reports that the EMA will investigate a possible link between GLP-1 drugs and suicidal thoughts.
Similar to Lilly, Novo Nordisk is affected by the EMA's upcoming discussion on the safety of GLP-1 drugs, which are a part of the company's portfolio. The potential regulatory scrutiny and negative publicity could adversely affect NVO's stock in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90